SOPHiA GENETICS

🚀 October has been an action-packed month at SOPHiA GENETICS! With Dr. Jurgi Camblong’s new Research Spotlight already making waves, inspiring customer stories, science hub insights, and global breast cancer awareness efforts, we’re showing in our social media newsletter how we're pushing the boundaries of data-driven medicine. 💌  Plus, there’s an exciting invitation waiting for you in this month’s social media newsletter — don’t miss out! Subscribe and read the latest edition here. #DataDrivenMedicine #LinkedInNewsletter #MonthlyNewsletter #CorporateNews

✈️ Next stop...Portugal! 🇵🇹 ➡️ Join us at the 13th Symposium of the European Scientific Foundation for Laboratory Hemato-Oncology (ESLHO) on November 7 at Convento do Beato in Lisbon, Portugal! 💡Don't miss the chance to stop by our booth, connect with our team of experts, and explore how the SOPHiA DDM™ Platform enables clinical researchers to save effort and time with our comprehensive, accurate, and future-proof end-to-end solutions in hemato-oncology and beyond! We look forward to meeting you in Lisbon! 🌍 #datadrivenmedicine #hematooncology #oncology #hematology #AIinhealthcare

🇬🇧 Next stop... London! Join us at the Royal College of Physicians, London for the 2024 Annual Conference of the British Society for Genetic Medicine (BGSM) on November 5! Stop by our booth to connect with our team and learn more about our latest news, new developments, and the future of the SOPHiA DDM™ Platform! We can't wait to meet you! #BGSM2024 #BGSM #Genomics #DataDrivenMedicine

🚀 Our SOPHiA DDM™ Exome Applications include tailored pipelines for the most common clinical and whole exome library prep kits, as well as bundle solutions that combine capture-based target enrichment with the analytical capabilities and advanced features of the SOPHiA DDM™ Platform. 💡 Expertly designed, these applications provide comprehensive coverage of multiple types of genomic variants in up to 19,425 genes, enabling data-informed decision-making. 🔗 Try it now for free: https://loom.ly/NXWQs0o

🇨🇦 Get ready, Vancouver! We are amped to be back at #AMPath24! 👋 Come meet our team to explore our latest advancements in solid tumor, MRD, and liquid biopsy applications. Learn how our SOPHiA DDM™️ Platform can empower you to streamline multimodal health data analysis. #Pathology #AMP24 #LiquidBiopsy #SolidTumor #Hematology Association for Molecular Pathology (AMP)

Save the date! Dr. Jurgi Camblong, Co-Founder and CEO of SOPHiA GENETICS, will host a fireside chat at Guggenheim's Healthcare Innovation Conference in Boston on November 12th. Join us virtually at 9:00 AM EDT / 3:00 PM CEST to gain insights into the future of data-driven medicine. 🔗 Register for the event here or find the link on our Investor Relations website: https://loom.ly/pcY0Qzw #DataDrivenMedicine #FiresideChat #Investors

📢 Mark your calendars for an insightful talk at #ASHG24 on Thursday, November 7! 🕛 12:00-12:30 pm 📍 Co-Lab Theatre 1 Join us for "Harnessing AI to Detect Challenging Variants and Expedite Exome Analysis Across Diverse Indications" — a must-attend session where our experts will showcase how SOPHiA DDM™ is pushing the boundaries of genetic analysis with advanced AI-powered tools. Hear from: Sevana Yaghoubian, Senior Director of Product Management, SOPHiA GENETICS, revealing the latest advancements in SOPHiA DDM™ and Alamut™ Visual Plus. José-Mario Capo-Chichi, Molecular Geneticist at Toronto General Hospital, demonstrating how versatile exome filtration is accelerating insights in hematologic malignancies. Tamara Maas, Senior Director of Bioinformatics, SOPHiA GENETICS, showcasing breakthrough cases of challenging variant detection across hereditary cancer, newborn screening, and pharmacogenomics. 🔗 Visit our website to learn more and book a meeting with our experts: https://loom.ly/q055gJs American Society of Human Genetics #DataDrivenMedicine #PrecisionGenomics #AIforHealthcare #WGS

I’m excited to share the second edition of Research Spotlight, highlighting findings from a multicenter trial published in The Lancet Haematology. The trial used SOPHiA DDM™ Dx Myeloid Solution, one of our CE-IVD applications.    The study focused on acute myeloid leukemia (#AML) patients aged 60-74, where allogenic hematopoietic stem-cell transplantation (HSCT) is the only curative option. However, accessing HSCT is often a challenge for older patients who less frequently reach remission, required for transplantation eligibility.     The recent trial of an Italian cohort tested whether first-line treatment with ventoclax plus decitabine could help achieve remission.    Throughout the trial, our SOPHiA DDM™ Dx Myeloid Solution was used to assess the biological characteristics of the patients’ AML and monitor residual disease. The results?    •  Ventoclax plus decitabine treatment achieved remission in 69% (64/93) of patients  •  57% (53/93) of patients ultimately underwent HSCT  •  Of the genes tested by NGS, only mutation of CSF3R showed any correlation with response to ventoclax plus decitabine, in this case a higher rate of non-response    These findings highlight ventoclax plus decitabine treatment as an effective bridge to HSCT for older patients.    You can read the publication here: https://lnkd.in/e7pKb2FH #ResearchSpotlight

🚀 At SOPHiA GENETICS, we’re shaping the future by investing in our emerging leaders! This October, we launched our new Emerging Leader Program with two highly interactive sessions that brought together diverse groups from different departments. The goal? To equip both experienced and aspiring leaders with hands-on tools to elevate their teams and lead with impact. From setting effective goals to creating a culture of trust and feedback, each participant left with concrete skills to apply right away. It was an incredible experience filled with lively exchanges and peer-to-peer learning, creating a true environment of growth and support. 🌱 We’re equally excited to announce upcoming remote sessions to make this opportunity accessible to our home-based emerging leaders. #LeadershipDevelopment #EmergingLeaders #TeamGrowth #LeadershipJourney Lucas Marques da Cunha, Antonio Ridi, Yvan Wenger, Jose Maria Rincon Garriz, Dragos Constantin, Mark Laver, Martin Vivies, Sofia Ridray, Erin Gunduz, M.Eng, PMP®, CLSSGB, Michella Ghassibe, Antonio Ridi, Anthony Sader, Christina Gkintzou, Ingrid Di Lorenzo, Floriane Consales Barras, Fanny Lanfranchi, Bita Khalili, Julie Romain, Simona Sevdina, Adrian Janiszewski, Nicola Dynes.

💡The SOPHiA DDM™ Platform complemented by Alamut™ Visual Plus offers streamlined Exome analysis workflows (from FASTQ file to variant report) for the efficient identification of genomic variants associated with rare and inherited diseases. ❗In a single workflow, the SOPHiA DDM™ Platform analyzes variants in mtDNA alongside SNVs, Indels, and CNVs in both coding and disease-relevant non-coding regions of nuclear DNA (nDNA). 🧬Alamut™ Visual Plus connects you to curated databases and prediction tools while providing enhanced variant visualization, so you can quickly confirm and report causative variants for complex conditions. ➡️ Learn more or get a demo SOPHiA DDM™ and Alamut™ Visual Plus today: https://lnkd.in/dj_F6_-k